This protocol addresses mild-to-moderate seborrheic dermatitis of the face or body in infants and young children — a population that requires a distinct therapeutic approach compared with adults.
The patient is an infant or young child presenting with mild-to-moderate seborrheic dermatitis affecting the face or body. This age group warrants particular caution: available data are scarce, and the potential for systemic drug absorption in newborns shapes the choice of treatment.
The protocol focuses on topically applied preparations — including certain natural antiinflammatory and antioxidant agents and/or emollient formulations — suited to the skin of infants and young children.
DOI: 10.2147/CCID.S284671
In infants and young children with mild-to-moderate facial/body SD, limited evidence supports the use of a topical pharmacological approach, due to scarce data and to the possibility of systemic drug absorption in newborns.
The use of natural antiinflammatory/antioxidants (eg, stearyl glycyrrhetinate, Aloe vera, vitamin E, Echinacea purpurea, lactoferrin) and/or emollient agents (eg, hyaluronic acid) as gel or cream, as well as AIAFp products, may be considered.
View source ↗